Preparation and quality control standard of clinical-grade neural progenitor/precursor cells-derived exosomes (2022 China version)

So far many people still believe that there is a lack of effective drugs or strategies to restore the dysfunction and/or the damaged structure of refractory neurological diseases. However, neurorestorative treatments are being tried to change the state. Transplanted neural progenitor/precursor cells (NPCs) as a novel therapy strategy played an important role in promoting neurological function restoration. Evidence demonstrated that the positive effects of grafted NPCs were mediated mainly by the releasing paracrine factors, especially exosomes, which were derived from NPCs. Exosomes are important paracrine molecules involved in cellular functions and cell-cell communications. This standard was set up by the Chinese Association of Neurorestoratology (CANR; Preparatory) and the China Committee of International Association of Neurorestoratology (IANR-China Committee) to provide rational guidance for technological transformation and clinical applications. In this standard, we highlighted the nature and features of NPC-derived exosomes, aimed to integrate the production, education, and research on the clinical-grade NPC-derived exosomes, promote the relevant standards and regulations established by the government and promote to make the world professional standards.